Tag: small-cap
FormFactor Stock Analysis: Buy or Sell? AI Demand, Customer Concentration & Valuation
FormFactor (FORM) is rated Hold as AI and HBM demand are driving strong growth, but the stock already discounts much of the upside. Rich valuation and customer concentration keep the risk-reward balanced.
Viking Therapeutics Stock Analysis: Buy or Sell? Cash Burn & Valuation
Viking Therapeutics (VKTX) is rated STRONG SELL because heavy cash burn is consuming a large cash balance while the stock still trades at a rich valuation. Phase 3 obesity progress remains the key swing factor, but the current risk/reward looks unfavorable.
Power Solutions International Stock Analysis: Buy or Sell? Valuation & Free Cash Flow
Power Solutions International (PSIX) is rated Hold as cash generation and profitability support the business, but the recovery is still uneven. The stock looks fairly valued after a 20.5% TTM revenue decline, so tariff exposure and execution risk remain the key watchpoints.
LifeStance Health Stock Analysis: Buy or Sell? Margins, Valuation & Growth
LifeStance Health Group, Inc. (LFST) is rated Hold as rapid revenue growth is offset by thin margins and a rich valuation. Payor concentration and only modest operating leverage remain the key items to watch.
Evolent Health Stock Analysis: Buy or Sell? Leverage, FCF Yield & Margin Risk
Evolent Health (EVH) carries a Strong Sell rating because its 25.4% FCF yield and strong cash generation do not offset 14.0x net debt/EBITDA and negative operating margin. The balance sheet remains the central risk, even with revenue growth and a cheap EV/revenue multiple.
Addus HomeCare Stock Analysis: Buy or Sell? Valuation, Margins & Reimbursement Risk
Addus HomeCare Corp. (ADUS) is rated Hold as steady execution and strong free cash flow are already reflected in the share price. Its low leverage is a plus, but valuation and reimbursement exposure leave limited upside.
Aveanna Healthcare Stock Analysis: Buy or Sell? Leverage, Valuation & Free Cash Flow
Aveanna Healthcare Holdings (AVAH) is rated Hold as growth remains solid, but 4.5x net debt/EBITDA limits upside. The business is improving operationally, yet leverage and only modest free cash flow keep the equity story balanced.
The Andersons Stock Analysis: Buy or Sell? Valuation, Free Cash Flow & EBITDA
The Andersons, Inc. (ANDE) carries a Hold rating as operating recovery improves but cash conversion remains negative. EBITDA is recovering, yet weak free cash flow and commodity margin volatility keep the valuation case in check.
Backblaze Stock Analysis: Buy or Sell? Valuation, Margins & Leverage
Backblaze (BLZE) is rated Hold as revenue growth remains solid but margins are still negative and leverage is elevated. The stock looks reasonably valued on sales, yet operating profitability has not improved enough to support a more aggressive call.
CRISPR Therapeutics Stock Analysis: Buy or Sell? Valuation, Cash Burn & Growth Outlook
CRISPR Therapeutics AG (CRSP) is rated STRONG SELL as its valuation already prices in a much faster commercial ramp than current revenue and cash generation support. With heavy cash burn and negative operating cash flow, the stock leaves little margin for error despite a strong balance sheet.